INSMED Inc (INSM) stock
INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30100% above fair value
$122.88+1.72 (+1.42%)
Close on Nov 16, 2026Market cap $26.96BP/E –Yield –
Insmed total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Insmed's total debt was $555.09M at Sep 30, 2026. For fiscal 2025 it was $540.96M, down 51.0% from the year before. Over ten years it grew 35.9% a year on average. The highest annual figure on record is $1.16B in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $540.96M | -51.0% |
| FY2024 | Dec 31, 2024 | $1.10B | -4.5% |
| FY2023 | Dec 31, 2023 | $1.16B | +2.7% |
| FY2022 | Dec 31, 2022 | $1.13B | +98.6% |
| FY2021 | Dec 31, 2021 | $566.59M | +59.0% |
| FY2020 | Dec 31, 2020 | $356.32M | +6.1% |
| FY2019 | Dec 31, 2019 | $335.94M | +6.1% |
| FY2018 | Dec 31, 2018 | $316.56M | +469.7% |
| FY2017 | Dec 31, 2017 | $55.57M | +1.4% |
| FY2016 | Dec 31, 2016 | $54.79M | +117.9% |
| FY2015 | Dec 31, 2015 | $25.14M | +1.1% |
| FY2014 | Dec 31, 2014 | $24.86M | +26.7% |
| FY2013 | Dec 31, 2013 | $19.62M | +48.5% |
| FY2012 | Dec 31, 2012 | $13.21M | – |
| FY2011 | Dec 31, 2011 | $0 | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $555.09M | +2.8% |
| Q2 FY2026 | Jun 30, 2026 | $543.51M | +0.9% |
| Q1 FY2026 | Mar 31, 2026 | $542.22M | -50.9% |
| Q4 FY2025 | Dec 31, 2025 | $540.96M | -51.0% |
| Q3 FY2025 | Sep 30, 2025 | $539.72M | -43.5% |
| Q2 FY2025 | Jun 30, 2025 | $538.51M | -54.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.11B | -5.0% |
| Q4 FY2024 | Dec 31, 2024 | $1.10B | -4.5% |
| Q3 FY2024 | Sep 30, 2024 | $954.83M | -16.8% |
| Q2 FY2024 | Jun 30, 2024 | $1.17B | +2.8% |
| Q1 FY2024 | Mar 31, 2024 | $1.16B | +2.7% |
| Q4 FY2023 | Dec 31, 2023 | $1.16B | +2.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.15B | +46.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.14B | +45.4% |
| Q1 FY2023 | Mar 31, 2023 | $1.13B | +44.6% |
| Q4 FY2022 | Dec 31, 2022 | $1.13B | +98.6% |
| Q3 FY2022 | Sep 30, 2022 | $784.80M | +40.7% |
| Q2 FY2022 | Jun 30, 2022 | $783.98M | +42.9% |
| Q1 FY2022 | Mar 31, 2022 | $783.16M | +116.6% |
| Q4 FY2021 | Dec 31, 2021 | $566.59M | +59.0% |
| Q3 FY2021 | Sep 30, 2021 | $557.60M | +58.8% |
| Q2 FY2021 | Jun 30, 2021 | $548.75M | +58.6% |
| Q1 FY2021 | Mar 31, 2021 | $361.58M | +6.1% |
| Q4 FY2020 | Dec 31, 2020 | $356.32M | +6.1% |
| Q3 FY2020 | Sep 30, 2020 | $351.13M | +6.1% |
| Q2 FY2020 | Jun 30, 2020 | $346.00M | +6.1% |
| Q1 FY2020 | Mar 31, 2020 | $340.94M | +6.1% |
| Q4 FY2019 | Dec 31, 2019 | $335.94M | +6.1% |
| Q3 FY2019 | Sep 30, 2019 | $331.00M | +6.1% |
| Q2 FY2019 | Jun 30, 2019 | $326.13M | +6.2% |
| Q1 FY2019 | Mar 31, 2019 | $321.31M | +6.1% |
| Q4 FY2018 | Dec 31, 2018 | $316.56M | +469.7% |
| Q3 FY2018 | Sep 30, 2018 | $311.86M | +463.0% |
| Q2 FY2018 | Jun 30, 2018 | $307.16M | +456.5% |
| Q1 FY2018 | Mar 31, 2018 | $302.71M | +450.4% |
| Q4 FY2017 | Dec 31, 2017 | $55.57M | +1.4% |
| Q3 FY2017 | Sep 30, 2017 | $55.39M | – |
| Q2 FY2017 | Jun 30, 2017 | $55.19M | – |
| Q1 FY2017 | Mar 31, 2017 | $54.99M | – |
| Q4 FY2016 | Dec 31, 2016 | $54.79M | – |
See a number that looks wrong?